|
|
|
51-200 employees
View all
|
|
Pharmaceuticals
|
|
200 Barr-Harbor Dr, Suite 200, Conshohocken, Pennsylvania 19428, US
|
|
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.
|
Madrigal Pharmaceuticals Email Formats | Example Email Formats | Percentage |
---|---|---|
{first} | [email protected] |
50%
|
The widely used Madrigal Pharmaceuticals email format is {first} (e.g. [email protected]) with 50% adoption across the company.
To contact Madrigal Pharmaceuticals customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.